To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women's Health Initiative (WHI) hormone therapy trials.
The guideline is jointly authored by the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).
The TORTUGA trial investigated the efficacy and safety of filgotinib for the treatment of patients with active ankylosing spondylitis.
The FDA has granted Fast Track designation for GLPG1972/S201086 for the treatment of patients with osteoarthritis.
The researchers found that use of trazodone correlated with similar rates of falls or major osteoporotic fractures compared with use of atypical antipsychotics.
The FDA approval of the ACTPen was supported by data from 2 studies: an open-label, randomized, 2-period, crossover Phase 1 study (N=188), and an open-label, non-randomized, observational Phase 4 human factors study (N=54).
The researchers found that compared with the placebo group, the DNM group had a higher percentage increase of L1 to L4 bone mineral density (5.92 ± 5.25% vs 2.92 ± 5.56%; P=.043) and wrist bone mineral density (−0.26 ± 5.31 vs −3.92 ± 8.71%; P=.035).
TNFi therapy failed to prevent the development of joint ankylosis despite a substantial reduction in inflammation with TNFi therapy.
The unadjusted prevalence rates of leisure-time physical inactivity and obesity were 56.5 and 50.1%, respectively, among adults with both arthritis and prediabetes.
The researchers found that from 2012 to 2017, there was an increase in the use of yoga (from 3.1 to 8.4%) and meditation (from 0.6 to 5.4%) during the previous 12 months. In 2017, girls were more likely than boys to have used yoga in the previous 12 months.
The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.
The FDA's approval was supported by data from analytical, preclinical, and clinical research showing that Hyrimoz matched the reference product's safety, efficacy, and quality.
To compare the characteristics of patients who discontinued TNFis with those who did not, researchers used the Corrona PsA/SpA Registry to identify patients with AS who were on a TNFi and had ≥2 follow-up visits.
Patients with gout who did not reach a serum uric acid level below 6 mg/dL had a 2.4-fold increased risk for death.
A reduction in risk for cardiovascular disease has been reported among patients with rheumatoid arthritis who are receiving concomitant therapy with methotrexate and biologic disease-modifying antirheumatic drugs.
Clinical improvements during treatment with TNF-α inhibitors was comparable between men and women with ankylosing spondylitis.
Compared with non-users, allopurinol use ≥300mg/day was correlated with a lower risk for developing chronic kidney disease stage ≥3.
Although the incidence rate of venous thromboembolism was numerically higher in patients treated with tofacitinib vs TNF inhibitors, the risk was not statistically significant.
Statin therapy was associated lower CRP levels in psoriatic arthritis treated with statins, possibly indicating decreased systemic inflammation.
Small but significant increases in weight (0.02lb) and BMI (0.006 lbl P<.001 for both) were observed over time. Moreover, a negative association between DAS28 and increased weight (-0.56) as well as BMI (-0.08; P<.001 for both) was reported, implying that an increase in weight was linked to lower disease activity.
The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and "potentially improved insulin sensitivity and glycemic profile."
The researchers found that compared with placebo, the proportion of IXEQ2W and IXEQ4W patients who achieved ASAS 40% response was significantly greater at week 16 (30.6 and 25.4%, respectively, vs 12.5%), with statistically significant differences seen as early as week 1 of treatment.
Researchers assessed the effect of replacing time not walking with walking at very-light, light, or moderate-to-vigorous intensities on the risk for TKA over 5 years.
Initiation of DMARD therapy within 6 months of symptom onset was associated with greater reduction in RA disease activity compared with later initiation.